Skip to main content

Table 1 Baseline patient characteristics

From: Niclosamide from an anthelmintic drug to a promising adjuvant therapy for diabetic kidney disease: randomized clinical trial

Characteristics

Niclosamide arm (n = 30)

Control arm (n = 30)

P value between arms

Gender, male, No. (%)

11 (36.7%)

12 (40%)

0.795

Age, mean ± SD, years

52.7 ± 5.2

54.2 ± 5.8

0.301

Body mass index, mean ± SD

28.7 ± 3.5

29.2 ± 3.9

0.564

Obese patients, No. (%)

10 (33.3%)

12 (40%)

0.54

Hypertensive patients, No. (%)

15 (50%)

13 (43%)

0.605

Diabetes duration, mean ± SD, years

9.5 ± 2

9.7 ± 3.2

0.739

Use of insulin, No. (%)

23 (76.7%)

25 (83.3%)

0.519

Fasting blood glucose, mean ± SD, mg/mL

163.3 ± 23.2

164.9 ± 26.1

0.803

Hemoglobin A1C, mean ± SD, %

9.7 ± 1.1

9.4 ± 1

0.254

Systolic blood pressure, mean ± SD, mm Hg

127.9 ± 10.4

133 ± 11.8

0.083

Diastolic blood pressure, mean ± SD, mm Hg

81.4 ± 7.3

88.2 ± 20

0.085

  1. Values are expressed as mean ± standard deviation or number (percent)